VOLUME 16 - NUMBER 4 / July-August (Original article / Artículo original)
Catherine Sarre-Lazcano, Médico adscrito, Dirección de Cirugía, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, México
Erika Ruiz-García, Department of Medical Oncology, Instituto Nacional de Cancerología, Mexico City; Department of Medical Oncology, Centro Oncológico Privado, Mexico City; Mexico
Rafael Medrano-Guzmán, Departamento de Sarcomas y Tumores de Tubo Digestivo; Unidad Médica de Alta Especialidad, Hospital de Oncología Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, México
Daniel Motola-Kuba, Hospital Médica Sur, Mexico City, Mexico
Heriberto Medina-Franco, Servicio de Cirugía Oncológica, Hospital Médica Sur, Ciudad de México, México
Background: A cooperative group was conformed between the digestive tract tumor departments from the Centro Médico Nacional Siglo XXI, Hospital Médica Sur, Instituto Nacional de Cancerología and the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Objective: To describe the institutional experience of the aforementioned centers in GIST (gastrointestinal stromal tumors) from 2000 to 2015 and analyze the prognostic factors. Methods: A retrospective, descriptive, analitic study was performed, registering demographic, clinic, surgical, pathological and follow-up data of patients with GIST diagnosis reported by each institution. Kaplan-Meier charts were constructed for the survival analysis, which were compared using the loig-rank test, considering p <0.05 as statistically significant. Results: A total of 274 cases were registered, with an even distribution between both sexes. The mean population age was 55 years, with the most frequent localization being the stomach (55,1%). Metastatic disease at diagnosis was found in 63 patients (28%). Mean size was 8.7 cm, with low-grade tumors being more frequent (36,5%). Mean follow-up was 42 months. Factors negatively associated with disease-free survival and overall survival were non-gastric localization, size >5 cm, high-grade tumors (>5 mitosis/field) and an intermediate or high recurrence risk. Conclusions: National experience is comparable to prognostic factors reported in international literature. Size was found to have a smaller impact in overall survival than tumoral grade.
Keywords: Tumores del estroma gastrointestinal; Índice mitótico; Tamaño tumoral; Imatinib; Estratificación de riesgo; Recurrencia; Sobrevida
